Perrigo's Q3 shows progress but updated outlook reflects divestiture and softness

What happened

Perrigo's Q3 2026 results showed sequential operating improvement under the Three-S plan, with market share gains in U.S. store brand OTC and key European brands. However, the full-year outlook was cut to reflect the planned infant formula divestiture, more cautious retailer inventory positioning, and continued softness in Europe. The divestiture of infant formula should simplify the portfolio but will remove a revenue stream and may not fully resolve quality and regulatory overhangs. The strategic review of Oral Care remains unresolved, adding uncertainty, while high leverage and the Irish tax dispute continue to pose significant risks. Despite the stock's depressed valuation, the path to sustainable earnings remains contingent on successful execution of cost savings and portfolio rationalization.

Implication

Over the long term, the accelerated portfolio simplification could improve focus and margins if the divestiture proceeds on reasonable terms and cash is used to reduce debt, but investors should demand evidence of deleveraging and resolution of the Irish tax case before adding risk. The company's high leverage leaves little margin for error, and softness in Europe may persist. The remaining OTC and self-care business has scale advantages, but shares are unlikely to re-rate until management demonstrates consistent earnings growth and lower risk profile. Investors should monitor quarterly execution against savings targets and any updates on strategic reviews; a successful exit from infant formula could be a positive catalyst, but a poorly negotiated deal could destroy value.

Thesis delta

The thesis shifts slightly toward cautious optimism as the portfolio simplification could improve focus, but the lower full-year outlook and unresolved reviews temper upside; we maintain a watchful stance until the infant formula transaction terms and Oral Care decision are disclosed.